Biocytogen Pharmaceuticals’ Eucure Biopharma Expands Partnership with Syncromune on Immunotherapies
China-based Biocytogen Pharmaceuticals (Beijing) Co., Ltd’s (HKG: 2315) wholly owned subsidiary, Eucure Biopharma, has announced...
Syncromune
Eucure Biopharma Partners with Syncromune on Intratumoral Immunotherapy
Eucure Biopharma, a wholly-owned subsidiary of Sino-US contract research organization (CRO) Biocytogen, has entered into...